The scientist’s investigation covers issues in Internal medicine, Cerebrospinal fluid, Pathology, Neurology and Dementia. His work deals with themes such as Endocrinology and Oncology, which intersect with Internal medicine. The various areas that he examines in his Cerebrospinal fluid study include Amyloid beta, Hyperintensity, Amyloid β peptide and Mass spectrometry.
His Pathology research incorporates elements of Biomarker and Pharmacology. His studies in Biomarker integrate themes in fields like Immunoassay, Meta-analysis, Disease and Immunology. His Neurology research is multidisciplinary, incorporating perspectives in Gastroenterology, Mini–Mental State Examination and Vascular dementia.
His primary areas of study are Cerebrospinal fluid, Internal medicine, Pathology, Biomarker and Dementia. His work in Cerebrospinal fluid tackles topics such as Neurology which are related to areas like Neurodegeneration and Cognition. His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine.
His Pathology research focuses on Gene isoform and how it connects with Pharmacology. His Biomarker research focuses on Bioinformatics and how it relates to Biomarker discovery. His Dementia study integrates concerns from other disciplines, such as Apolipoprotein E, Area under the curve and Cohort.
His primary scientific interests are in Internal medicine, Cerebrospinal fluid, Dementia, Biomarker and Oncology. His research integrates issues of Gastroenterology and Neurology in his study of Internal medicine. His Cerebrospinal fluid research is multidisciplinary, incorporating elements of Extracellular matrix and Endocrinology.
His biological study spans a wide range of topics, including Alzheimer's disease, Neurodegeneration and SNP. The concepts of his Biomarker study are interwoven with issues in Positron emission tomography, Area under the curve and Pathology. Ulf Andreasson works mostly in the field of Oncology, limiting it down to concerns involving Neuroimaging and, occasionally, Clinical trial and Peripheral.
Ulf Andreasson mainly focuses on Dementia, Internal medicine, Neurology, Neurodegeneration and Cognitive decline. His Dementia research incorporates themes from Alzheimer's disease and Biomarker. His study in Internal medicine is interdisciplinary in nature, drawing from both Neuroimaging and Oncology.
He combines subjects such as Cognition, Blood biomarkers and Intensive care medicine with his study of Neurodegeneration. His Cognitive decline research is multidisciplinary, relying on both Apolipoprotein E, Amyloid beta and Neuroscience. He works mostly in the field of Clinical trial, limiting it down to topics relating to Alzheimer's Disease Neuroimaging Initiative and, in certain cases, Cerebrospinal fluid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson;Ronald Lautner;Ulf Andreasson;Annika Öhrfelt.
Lancet Neurology (2016)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle;Christian Barro;Ulf Andreasson;Tobias Derfuss.
Clinical Chemistry and Laboratory Medicine (2016)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric;Christopher H. van Dyck;Stephen Salloway;Niels Andreasen.
JAMA Neurology (2012)
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson;Ulf Andreasson;Staffan Persson;Hiroyuki Arai.
Alzheimers & Dementia (2011)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall;Annika Öhrfelt;Radu Constantinescu;Ulf Andreasson.
JAMA Neurology (2012)
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson;Niklas Mattsson;Ulf Andreasson;Staffan Persson;Maria C. Carrillo.
Alzheimers & Dementia (2013)
Prediction of Alzheimer's Disease Using the CSF Abeta42/Abeta40 Ratio in Patients with Mild Cognitive Impairment.
Oskar Hansson;Henrik Zetterberg;Peder Buchhave;Ulf Andreasson.
Dementia and Geriatric Cognitive Disorders (2007)
Plasma tau levels in Alzheimer's disease
Henrik Zetterberg;Henrik Zetterberg;David Wilson;Ulf Andreasson;Lennart Minthon.
Alzheimer's Research & Therapy (2013)
Evaluation of plasma A beta(40) and A beta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
Oskar Hansson;Oskar Hansson;Henrik Zetterberg;Eugeen Vanmechelen;Hugo Vanderstichele.
Neurobiology of Aging (2010)
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography.
Sebastian Palmqvist;Henrik Zetterberg;Kaj Blennow;Susanna Vestberg.
JAMA Neurology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: